StreetInsider.com News Articles

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced the adoption of time-lapse incubation technology at its Wisconsin clinic. This integration reflects INVO’s commitment to providing high-quality, modern laboratory care and innovative patient solutions, and to investing in laboratory excellence and clinical quality across its growing network of clinics.

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic

Thu, 05 Mar 2026 09:00:00 +0000

“INVO Fertility is proud to introduce this technology as

INVO Fertility’s Wisconsin Clinic Joins Progyny Network

Tue, 03 Mar 2026 08:45:00 +0000

MIDDLETON, Wis. and SARASOTA, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced reproductive treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that its Wisconsin Fertility Institute (WFI) clinic has joined the Progyny network.

Progyny provides fertility and family-building benefits to an estimated 7.2 million covered lives through over 600 employers and plan sponsors nationwide. WFI’s participation in the Progyny network significantly expands the clinic’s access to employer-sponsored patients

INVO Fertility’s Wisconsin Clinic Joins Progyny Network

Tue, 03 Mar 2026 08:45:00 +0000

INVO Fertility’s Wisconsin Clinic Joins Progyny Network

Tue, 03 Mar 2026 08:45:00 +0000

INVO Fertility’s Wisconsin Clinic Joins Progyny Network

Tue, 03 Mar 2026 08:45:00 +0000

Form 8-K INVO Fertility, Inc. For: Feb 18

Tue, 24 Feb 2026 09:01:00 +0000

si-local-file:///var/storage/secattach/20260224/26047908.html

Form 8-K INVO Fertility, Inc. For: Feb 18

Tue, 24 Feb 2026 09:01:00 +0000

si-local-file:///var/storage/secattach/20260224/26047908.html

INVO Fertility completes $760,000 acquisition of Indiana clinic

Thu, 19 Feb 2026 08:33:23 +0000

INVO Fertility Inc. (NASDAQ: IVF) completed its acquisition of Family Beginnings P.C., an Indiana-based fertility clinic, according to a company statement. The transaction closed under terms announced December 17, 2025.

INVO acquired the non-clinical assets of Family Beginnings for $760,000 through a combination of cash and preferred stock. Dr. James Donahue will continue leading clinic operations under a multi-year agreement.

Family Beginnings generated approximately $1 million in revenue and $200,000 in net income for the nine months ended September 30, 2025. This represented roughly 18% of INVO's clinic revenue for the same period.

The Indiana clinic offers reproductive services including in vitro fertilization,

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”

Thu, 19 Feb 2026 08:30:00 +0000

SARASOTA, Fla., Feb. 19, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that it has successfully closed the previously announced acquisition of Family Beginnings, P.C., a respected fertility clinic serving patients across Indiana and the broader Midwest.

The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.

Founded more than a decade ago, Family Beginnings has built a strong reputation

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”

Thu, 19 Feb 2026 08:30:00 +0000

The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.

Founded more than a decade ago, Family Beginnings has built a strong reputation

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”

Thu, 19 Feb 2026 08:30:00 +0000

The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.

Founded more than a decade ago, Family Beginnings has built a strong reputation

INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”

Thu, 19 Feb 2026 08:30:00 +0000

The transaction was completed in accordance with the terms of the definitive purchase agreement first announced on December 17, 2025.

Founded more than a decade ago, Family Beginnings has built a strong reputation

Form SCHEDULE 13G INVO Fertility, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:51:00 +0000

si-local-file:///var/storage/secattach/20260217/26016335.html

Form SCHEDULE 13G INVO Fertility, Inc. Filed by: ARMISTICE CAPITAL, LLC

Tue, 17 Feb 2026 21:51:00 +0000

si-local-file:///var/storage/secattach/20260217/26016335.html

Form 424B3 INVO Fertility, Inc.

Thu, 12 Feb 2026 17:17:00 +0000

si-local-file:///var/storage/secattach/20260212/25993374.html

Form 424B3 INVO Fertility, Inc.

Thu, 12 Feb 2026 17:17:00 +0000

si-local-file:///var/storage/secattach/20260212/25993374.html

INVO Fertility receives patent for modified INVOcell device design

Wed, 11 Feb 2026 08:31:47 +0000

INVO Fertility Inc. (NASDAQ: IVF) announced the issuance of U.S. Patent No. 12,544,204 B2 for a modified version of its INVOcell device. The patent became effective February 10, 2026, and provides intellectual property protection through 2040.

The INVOcell is an intravaginal culture system that received FDA clearance in 2015 for assisted reproductive care. The device allows fertilization and early embryo development to occur within a woman's body rather than in a laboratory setting. In 2023, the FDA approved a labeling update extending the recommended incubation period from three to five days.

The original INVOcell design included both a main chamber and a

INVO Fertility Announces Patent Issuance for Modified INVOcell® Device

Wed, 11 Feb 2026 08:30:00 +0000

SARASOTA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced the final issuance of a U.S. patent covering a modified version of its proprietary INVOcell® device. The patent (U.S. Patent No. 12,544,204 B2) became effective on February 10, 2026, providing intellectual property protection on the INVOcell device through 2040.

INVOcell is the world’s first FDA-cleared intravaginal culture (IVC) system—a patented medical device for assisted reproductive care that allows fertilization